Intas launches of Topical TOFATAS – a DCGI-approved, Tofacitinib Ointment 2% w/w for the treatment of mild to moderate Atopic Dermatitis (AD) in patients 18 years and above having flare-ups of the disease.
Atopic Dermatitis (AD) is a chronic inflammatory, non-communicable, and relapsing skin disease. Atopic Dermatitis is a multifactorial disease arising from a complex interaction between genetic, environmental, and immunological factors. Despite unmet needs, approximately 15 years have passed since a topical therapy with a new mechanism of action for atopic dermatitis (AD) has been introduced in India. The quality of life of the patients suffering from Atopic Dermatitis (AD) is compromised due to factors like consistent itching, sleep disturbances, poor performance at school/work, and disturbed social, mental, and emotional functioning.
Safety issues with existing therapies (Topical Corticosteroids/Topical Calcineurin Inhibitors) in the management of AD have always been challenge in the long run as they are accompanied by increased risks of side effects which impact the patient's quality of life. Furthermore, due to the distinct characteristics of Atopic Dermatitis, its management remains difficult.
As a frontrunner in the dermatology therapy domain, Intas boldly and successfully endeavored to bridge this critical treatment gap by investing in extensive research efforts to develop and formulate Topical TOFATAS - a drug that delivers the desired outcome and the clinical benefits for Atopic Dermatitis patients. A Phase III clinical study of Topical TOFATAS (Tofacitinib Ointment 2% w/w) in Atopic Dermatitis patients in India showed remarkable safety and efficacy.
